Yousif Capital Management LLC Sells 9,689 Shares of Johnson & Johnson $JNJ

Key Points

• Yousif Capital Management trimmed its stake in Johnson & Johnson by 3.0%, selling 9,689 shares and ending the quarter with 310,460 shares worth $67.745 million (JNJ is ~0.7% of its portfolio and its 14th largest holding).
• Analyst sentiment is mildly positive with a consensus rating of “Moderate Buy” and an average price target of $238.17; several firms raised targets recently (e.g., Morgan Stanley to $267, Barclays to $234).
• Company insiders sold 30,142 shares in the last quarter (about $7.36M), leaving insiders with 0.16% ownership, while institutional investors own roughly 69.55% of the stock.

Yousif Capital Management LLC decreased its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 310,460 shares of the company's stock after selling 9,689 shares during the quarter. Johnson & Johnson comprises approximately 0.7% of Yousif Capital Management LLC's investment portfolio, making the stock its 14th largest position. Yousif Capital Management LLC's holdings in Johnson & Johnson were worth $67,745,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Brighton Jones LLC increased its stake in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares in the last quarter. United Bank increased its stake in shares of Johnson & Johnson by 110.7% in the 1st quarter. United Bank now owns 9,279 shares of the company's stock valued at $1,539,000 after acquiring an additional 4,876 shares in the last quarter. Sivia Capital Partners LLC increased its stake in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company's stock valued at $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. increased its stake in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company's stock valued at $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. increased its position in Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company's stock valued at $11,255,000 after buying an additional 6,584 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Barclays boosted their target price on Johnson & Johnson from $217.00 to $234.00 and gave the company an "equal weight" rating in a research report on Thursday, March 19th. Wall Street Zen lowered Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Scotiabank restated an "outperform" rating on shares of Johnson & Johnson in a research note on Thursday, January 22nd. Sanford C. Bernstein boosted their price target on shares of Johnson & Johnson from $208.00 to $225.00 and gave the company a "market perform" rating in a research note on Friday, January 23rd. Finally, Morgan Stanley boosted their price target on shares of Johnson & Johnson from $262.00 to $267.00 and gave the company an "overweight" rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $238.17.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $238.34 on Friday. The company has a debt-to-equity ratio of 0.48, a quick ratio of 0.77 and a current ratio of 1.03. The stock has a 50 day moving average price of $241.29 and a two-hundred day moving average price of $215.26. The firm has a market capitalization of $574.06 billion, a P/E ratio of 21.57, a P/E/G ratio of 2.36 and a beta of 0.34. Johnson & Johnson has a 52 week low of $146.12 and a 52 week high of $251.71.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Saturday, January 31st. The company reported $2.46 EPS for the quarter. The firm had revenue of $24.28 billion during the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Morgan Stanley raised its price target to $267 and kept an "Overweight" rating, signaling roughly double-digit upside versus current levels and supporting buy-side interest. Read More.
• Positive Sentiment: Other broker notes (Guggenheim, Citi, and various upgrades) have recently pushed bullish research and helped intraday rallies. Read More.
• Positive Sentiment: Commercial/MedTech catalyst — J&J launched the VARIPULSE Pro pulsed field ablation system in Europe after CE mark approval, adding potential device revenue upside and real‑world evidence generation. Read More.
• Positive Sentiment: Dividend profile remains a tailwind for income investors — long streak of annual increases (>60 years) supports total‑return buyers. Read More.
• Neutral Sentiment: Fair‑value/target updates are moving modestly (consensus fair value around ~$241.7) — analysts are lifting some targets while flagging execution as the next focus, keeping valuation views mixed. Read More.
• Neutral Sentiment: Market is positioning for Q1 earnings — multiple previews and Wall Street estimate rundowns are circulating; that typically increases volatility into the print. Read More.
• Negative Sentiment: Some analysts and commentators are cautioning that this is “time to sell the rally” into Q1, arguing upside expectations may be priced in and that near‑term catalysts could disappoint. Read More.
• Negative Sentiment: Ongoing risks — litigation exposure, biosimilar competition and pricing pressure are repeatedly flagged as potential earnings/headwind items that could cap upside. Read More.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total value of $1,508,287.83. Following the completion of the sale, the executive vice president owned 23,003 shares in the company, valued at $5,598,700.17. This represents a 21.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Timothy Schmid sold 1,322 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,251,310.02. The trade was a 4.94% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.